Ask about this productRelated genes to: HOXA5 Blocking Peptide
- Gene:
- HOXA5 NIH gene
- Name:
- homeobox A5
- Previous symbol:
- HOX1C, HOX1
- Synonyms:
- -
- Chromosome:
- 7p15.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-06-15
- Date modifiied:
- 2015-09-07
Related products to: HOXA5 Blocking Peptide
Related articles to: HOXA5 Blocking Peptide
- Despite the proliferation of prognostic gene signatures for glioma, clinical translation remains stalled by poor reproducibility and overfitting. In this study, we address this stability crisis by developing a robust "Dual-Signature Framework" using stability selection-a rigorous resampling method-rather than standard regression. Analyzing RNA-seq data from 1351 patients across the TCGA (n = 694) and CGGA (n = 657) cohorts, we constructed two distinct models. The primary 20-gene "Data-Driven" signature achieved superior predictive accuracy (C-index: 0.7392), significantly outperforming 14 published benchmark models and the current best single-gene predictor (HOXA5). In parallel, we derived a 7-gene "Biology-Driven" signature (including HOXA5, CHI3L1, MMP14) that retained 98% of the predictive power (C-index: 0.7252) while prioritizing mechanistic interpretability. Both models successfully stratified patients into distinct risk groups with high statistical significance (Log-rank p < 0.001) in external validation. Comprehensive subgroup analyses across 19 clinical and molecular subgroups demonstrated robust performance (C-index range: 0.59-0.85), with extended calibration analysis confirming excellent probability estimation (Brier score 0.20 for 5-year predictions). By integrating stability-driven feature selection with biological pathway constraints, this study provides a reproducible, high-performance alternative to unstable "black box" models, offering a translation-ready tool for personalized glioma risk assessment. - Source: PubMed
Publication date: 2026/05/12
D'Costa Romeo MaclineIslam Md ShafiqulIslam Md Masudul - Chemoimmunotherapy for small cell lung cancer (SCLC) is initially effective; however, relapse is common. Patterns of progression may serve to prognosticate outcomes and identify biomarkers for relapsed SCLC. - Source: PubMed
Publication date: 2026/04/03
Kumar PareshSlaven James EZhou TianhaoTran MyaShields Misty D - Mediastinal gray zone lymphoma (MGZL) is a rare B-cell lymphoma characterized by overlapping clinicopathologic and molecular features of primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (CHL). Under current WHO-HEMA5 and International Consensus Classification (ICC) frameworks, MGZL is restricted to EBV-negative lymphomas arising in the mediastinum. This review summarizes current evidence on epidemiology, clinical presentation, pathology, molecular characteristics, diagnostic challenges, and therapeutic approaches to MGZL, with data derived from retrospective series, limited prospective cohorts, and recent molecular studies. MGZL predominantly affects young adults and commonly presents with bulky mediastinal disease. Diagnosis is challenging due to transitional morphology, pleomorphic Reed-Sternberg-like cells, and variable expression of B-cell and activation markers. Molecular studies demonstrate shared alterations with PMBL and CHL, including 9p24.1 (JAK2/PD-L1/PD-L2) gains, while additional reported features such as HOXA5 hypomethylation and MYC copy number gains support its biological distinctiveness, although evidence remains limited. Frontline treatment commonly involves intensive chemoimmunotherapy regimens such as DA-EPOCH-R; however, outcomes remain inferior to PMBL and CHL, with 5-year overall survival rates of approximately 40-60%. Relapsed or refractory disease frequently requires salvage chemotherapy and autologous stem cell transplantation. Immune-based therapies, including brentuximab vedotin and PD-1 inhibitors, have shown promising activity, particularly in combination. MGZL remains a diagnostically challenging and therapeutically complex lymphoma with inferior outcomes compared with related mediastinal lymphomas. Advances in molecular profiling and immunotherapy offer promising avenues toward more personalized treatment; however, prospective clinical trials and international collaboration are urgently needed to establish evidence-based management strategies for this rare entity. - Source: PubMed
Publication date: 2025/12/31
Zorlu TugbaSeyhan MertAbdullayeva NigarUlas TurgaySinan Dal Mehmet - Allergic asthma pathogenesis encompasses systemic immune, metabolic, and epithelial barrier dysfunction; however, minimally invasive tools to longitudinally explore these processes remain limited. - Source: PubMed
Publication date: 2026/01/06
Liu DanielKim MadelineDel Duca EsterBar JonathanLau MeganLargen JosephAgache IoanaGuttman-Yassky Emma - As dementia cases continue to rise, effective prevention strategies are urgently needed. However, objective biomarkers that directly reflect lifestyle factors remain limited. Life's Essential 8 (LE8) is a composite of modifiable cardiovascular health metrics, and lower LE8 has been consistently associated with increased risk of dementia. In this study, we aimed to identify DNA methylation biomarkers associated with LE8 scores and investigate their relevance for dementia risk. - Source: PubMed
Publication date: 2025/12/29
Lukacsovich DavidWang LiyongYoung Juan IZhang WeiGomez LissetteSchmidt Michael AGardener HannahAgudelo ChristianDueker NicoleElfassy TaliGibbs CarlaScott Sadeaqua SMartin Eden RKunkle Brian WChen X StevenBlanton SusanRundek TatjanaWang Lily